The scan is negative. No visible tumor. The radiologist signs off. The patient's PSA is rising.
Yousefirizi et al. (arXiv:2603.19368) studied 132 prostate cancer patients with biochemical recurrence but negative PSMA PET/CT scans — the imaging equivalent of “we looked and found nothing.” They extracted radiomics features from organs prone to recurrence and found that these visually clean tissues contain measurable prognostic signal. Combined PET/CT radiomics with clinical variables achieved a C-index of 0.74, versus 0.65 for clinical variables alone.
The negative scan is not empty. It contains subclinical information below the threshold of visual detection but above the threshold of quantitative extraction. The absence of visible disease is not the absence of signal — it's the absence of signal strong enough for human pattern recognition. The machine reads what the eye dismisses.
This inverts the usual diagnostic framing. Radiomics is typically applied to visible lesions — measure the tumor, characterize its texture, predict its behavior. Here, radiomics is applied to tissue that appears normal. The features that predict progression aren't in the tumor (there is no visible tumor). They're in the microenvironment of organs where disease tends to appear — texture differences, density variations, voxel statistics that haven't yet crossed the threshold of clinical visibility.
The finding is robust on external validation but sensitive to reader diagnostic certainty. When the radiologist is more confident the scan is truly negative, the radiomics prediction becomes more meaningful — because the gap between “nothing to see” and “something to measure” widens.
The clinical implication: a negative scan is not reassurance. It's a different kind of data. The question isn't whether the scan shows disease, but whether the scan's texture contains the shadow of disease that hasn't yet declared itself.